Find your next paid study

Johnson & Johnson Enterprise Innovation Inc.NCT04892173

Neoplasms, Solid TumorBreast Neoplasms, Triple-NegativeSquamous Cell Carcinoma of Skin+4 more

A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors

The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help de…

Onchilles Pharma IncNCT07339176

Observational

A Single Arm, Open Label Clinical Study to Assess the Safety and Efficacy of Intratumoral Alpha DaRT224 for the Treatment of Immunocompromised Patients With Cutaneous Squamous Cell Carcinoma

This is a multi-center clinical study enrolling up to 28 participants. The primary objectives are to determine the objective response rate (ORR) established by…

Squamous Cell CarcinomaAlpha RadiationImmunocompromised+3 more

Alpha Tau Medical LTD.NCT06615635

Phase I, Dual Arm, Open-Label, Trial of Intralesional 5-Fluorouracil (5FU) and Intralesional 5FU Combined With Topical Calcipotriene in Patients With Squamous Cell Carcinoma (SCC) of the Lower Extremities

This clinical trial proposes to evaluate a relatively unexplored approach to treatment of squamous cell carcinoma (SCC) on the lower extremities. The strategy …

Carcinoma, Squamous Cell

Melissa Pugliano-MauroNCT03370406

~$10 – $7,500

Head and Neck NeoplasmsCarcinoma, Squamous CellNeoplasm Recurrence, Local+3 more

A Phase I Study of Zanzalintinib With Pembrolizumab and Cetuximab in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

This Phase I clinical trial evaluates the safety, tolerability, and optimal dosing of Zanzalintinib in combination with Pembrolizumab and Cetuximab in patients…

University of ChicagoNCT06912087

~$10 – $6,250

Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Anal CanalColorectal Cancer+8 more

First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this…

Bicara TherapeuticsNCT04429542

LCCC 2044: Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC

The primary goal of this study is to examine whether recurrence of HPV-associated OPSCC can be predicted by two factors: 1) mutations in genes called TRAF3 and…

Oropharyngeal Squamous Cell CarcinomaCarcinoma, Squamous CellHead and Neck Squamous Cell Carcinoma+1 more

UNC Lineberger Comprehensive Cancer CenterNCT04564989

~$10 – $750

Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma

Circulating tumor DNA (ctDNA) is a blood-based test that measures dying or dead cancer cells that are already circulating in the blood. In this study, the inve…

Head and Neck NeoplasmCarcinoma, Squamous Cell

UNC Lineberger Comprehensive Cancer CenterNCT04099290

~$10 – $750

Phase 2

A Phase II, Multi-center, Single Arm Trial of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Locally Advanced and/or Metastatic Anorectal Squamous Cell Carcinoma (ASCC) After Progression on First Line Chemotherapy.

The purpose of this study is to gather information on the safety and effectiveness of lenvatinib combined with pembrolizumab in anal/rectal cancer that has spr…

Carcinoma, Squamous CellAnorectal Cancer